It is also a modulator of the HER2 receptor in small cell lung cancer (SCLC), and its under-expression is associated with the anti-tumor effects of cytotoxic drugs in HER2-positive SCLC [118]. This evidence concerns the gene ERBB2 and small cell lung carcinoma.